top of page
  • Writer's picturecmrouth

FDA Accepts Drug in Phase 1 study INI1-Negative Tumors, Including AT/RT

Updated: Feb 5, 2020

Epizyme, Inc. a clinical stage biopharmaceutical company creating novel epigenetic therapies for patients with cancer, today announced the U.S. Food and Drug Administration (FDA) has accepted the company’s investigational new drug (IND) application for tazemetostat for the treatment of adults and pediatric patients with INI1-negative tumors or synovial sarcoma. In the second half of 2015, Epizyme plans to initiate a multi-center phase 2 study in adults and a multi-center phase 1 study in children to evaluate tazemetostat in patients with relapsed or refractory INI1-negative tumors or synovial sarcoma.

24 views0 comments
bottom of page